Podcasts about antipdl1

  • 4PODCASTS
  • 25EPISODES
  • 6mAVG DURATION
  • ?INFREQUENT EPISODES
  • Dec 10, 2013LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about antipdl1

Latest podcast episodes about antipdl1

GRACEcast Lung Cancer Video
Squamous Lung Cancer, Part 4: Immunotherapy (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Dec 10, 2013 7:07


Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

GRACEcast
Squamous Lung Cancer, Part 4: Immunotherapy (audio)

GRACEcast

Play Episode Listen Later Dec 10, 2013 7:06


Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

GRACEcast Lung Cancer Audio
Squamous Lung Cancer, Part 4: Immunotherapy (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Dec 10, 2013 7:06


Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

GRACEcast ALL Subjects audio and video
Squamous Lung Cancer, Part 4: Immunotherapy (video)

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Dec 10, 2013 7:07


Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

GRACEcast ALL Subjects audio and video
Squamous Lung Cancer, Part 4: Immunotherapy (audio)

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Dec 10, 2013 7:06


Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

GRACEcast
Squamous Lung Cancer, Part 4: Immunotherapy (video)

GRACEcast

Play Episode Listen Later Dec 10, 2013 7:07


Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

GRACEcast ALL Subjects audio and video
How should we integrate new immunotherapies into treatment strategies for lung cancer?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jul 4, 2013 4:17


Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.

GRACEcast Lung Cancer Video
How should we integrate new immunotherapies into treatment strategies for lung cancer?

GRACEcast Lung Cancer Video

Play Episode Listen Later Jul 4, 2013 4:17


Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.

GRACEcast
How should we integrate new immunotherapies into treatment strategies for lung cancer?

GRACEcast

Play Episode Listen Later Jul 4, 2013 4:17


Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.

GRACEcast
Can we harness our immune system to fight NSCLC?

GRACEcast

Play Episode Listen Later Jun 19, 2013 8:45


Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.

GRACEcast Lung Cancer Video
Can we harness our immune system to fight NSCLC?

GRACEcast Lung Cancer Video

Play Episode Listen Later Jun 19, 2013 8:45


Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.

GRACEcast ALL Subjects audio and video
Can we harness our immune system to fight NSCLC?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jun 19, 2013 8:45


Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.

GRACEcast Lung Cancer Video
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years

GRACEcast Lung Cancer Video

Play Episode Listen Later Mar 25, 2013 1:50


Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

GRACEcast ALL Subjects audio and video
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Mar 25, 2013 1:50


Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

GRACEcast
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years

GRACEcast

Play Episode Listen Later Mar 25, 2013 1:50


Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

GRACEcast ALL Subjects audio and video
Drs. Ross Camidge and Corey Langer: Which New Targets and Therapies Could We Bring to the Lung Cancer Clinic in the Near Future?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Mar 7, 2013 2:07


Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.

GRACEcast
Drs. Ross Camidge and Corey Langer: Which New Targets and Therapies Could We Bring to the Lung Cancer Clinic in the Near Future?

GRACEcast

Play Episode Listen Later Mar 7, 2013 2:07


Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.

GRACEcast Lung Cancer Video
Drs. Ross Camidge and Corey Langer: Which New Targets and Therapies Could We Bring to the Lung Cancer Clinic in the Near Future?

GRACEcast Lung Cancer Video

Play Episode Listen Later Mar 7, 2013 2:07


Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.

GRACEcast ALL Subjects audio and video
Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Mar 1, 2013 1:36


Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.

GRACEcast
Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?

GRACEcast

Play Episode Listen Later Mar 1, 2013 1:36


Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.

GRACEcast Lung Cancer Video
Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?

GRACEcast Lung Cancer Video

Play Episode Listen Later Mar 1, 2013 1:36


Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.

GRACEcast Lung Cancer Video
ASCO 2012 LC Highlights: Dr. Joel Neal on Anti-PD-1 Immunotherapy for Advanced NSCLC (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Sep 5, 2012 7:41


Dr. Joel Neal describes the very encouraging data on anti-PD-1 immunotherapy with BMS-936558/MDX-1106 in patients with advanced non-small cell lung cancer (NSCLC).

GRACEcast Lung Cancer Audio
ASCO 2012 LC Highlights: Dr. Joel Neal on Anti-PD-1 Immunotherapy for Advanced NSCLC (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Sep 4, 2012 7:40


Dr. Joel Neal describes the very encouraging data on anti-PD-1 immunotherapy with BMS-936558/MDX-1106 in patients with advanced non-small cell lung cancer (NSCLC).

GRACEcast Lung Cancer Audio
Immunotherapy for Lung Cancer: Yervoy, anti-PD-1, Reolysin, & Talactoferrin by Dr. J. Brahmer (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Jun 14, 2012 23:36


Dr. Julie Brahmer reviews science and early trial results for immunotherapies for lung cancer ranging from cancer vaccines to anti-cancer viruses.

GRACEcast Lung Cancer Video
Immunotherapy for Lung Cancer: Yervoy, anti-PD-1, Reolysin, & Talactoferrin by Dr. J. Brahmer (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Jun 14, 2012 23:37


Dr. Julie Brahmer reviews science and early trial results for immunotherapies for lung cancer ranging from cancer vaccines to anti-cancer viruses.